Skip to Content

Iohexol Pregnancy and Breastfeeding Warnings

Iohexol is also known as: Myelo-Kit, Omnipaque 140, Omnipaque 180, Omnipaque 180 Redi-Unit, Omnipaque 210, Omnipaque 240, Omnipaque 240 Redi-Unit, Omnipaque 300, Omnipaque 350, Omnipaque Flexipak, Oraltag

Iohexol Pregnancy Warnings

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: Not assigned.
US FDA pregnancy category: B

Reproduction studies have been performed in rats and rabbits with up to 100 times the recommended human dose. No evidence of direct or indirect impaired fertility, harm to the embryo, fetus, or to the course of gestation and peri and postnatal development has been demonstrated. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Iohexol Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Yes

Comments:
-Bottle feedings may be substituted for breast feedings for 24 hours following administration of this drug; however, some experts feel that breast feeding may be continued normally when iodinated contrast media are given to the mother.
-The effects in the nursing infant are unknown.

Contrast media are poorly excreted in human breast milk and minimal amounts are absorbed by the intestine. Approximately 0.5% of the weight adjusted maternal dose is excreted in breast milk during 24 hours after injection of this drug. The amount ingested by the baby in the first 24 hours after injection corresponds to only 0.2% of the pediatric dose.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide